1. Home
  2. TCMD vs DCTH Comparison

TCMD vs DCTH Comparison

Compare TCMD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$22.56

Market Cap

548.2M

Sector

Health Care

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$15.65

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
DCTH
Founded
1995
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
548.2M
578.4M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
TCMD
DCTH
Price
$22.56
$15.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
★ $36.00
$22.00
AVG Volume (30 Days)
240.5K
★ 327.8K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
17.14
★ 107.53
EPS
★ 0.26
0.04
Revenue
N/A
N/A
Revenue This Year
$11.60
$24.54
Revenue Next Year
$9.14
$33.15
P/E Ratio
★ $88.04
$402.00
Revenue Growth
N/A
N/A
52 Week Low
$13.48
$8.12
52 Week High
$37.77
$17.42

Technical Indicators

Market Signals
Indicator
TCMD
DCTH
Relative Strength Index (RSI) 45.05 44.61
Support Level $21.29 $9.98
Resistance Level $27.67 $16.51
Average True Range (ATR) 0.66 0.45
MACD 0.23 -0.13
Stochastic Oscillator 74.23 10.39

Price Performance

Historical Comparison
TCMD
DCTH

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: